Latest Information Update: 12 Jan 2017
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Proto oncogene protein c-akt inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 10 Jan 2017 Yonsei University plans a phase II trial for Solid tumours (Late-stage disease, Recurrent, Second-line therapy or greater) in South Korea (PO) (NCT03017521)
- 01 Feb 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in Japan (PO) (JapicCTI152780)